Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
Key Highlights
- ➤VTAMA EASI75 response reached 57.8%-70.0% across evaluated subgroups
- ➤VTAMA vIGA-AD response reached 45.3%-53.9% across evaluated subgroups
- ➤VTAMA PP-NRS response reached 55.0%-64.9% across evaluated subgroups
- ➤Pooled Phase 3 analysis included 813 adults and children with moderate-to-severe atopic dermatitis
- ➤FDA approved VTAMA for atopic dermatitis in adults and pediatric patients aged two and older
Expert Statements
Luz Fonacier, Professor, Department of Medicine at NYU Grossman Long Island School of Medicine and lead author
“Physicians want assurances that the therapies they recommend have broad applicability across the diverse patients they see in their offices daily.”
Luz Fonacier, Professor, Department of Medicine at NYU Grossman Long Island School of Medicine and lead author
“The consistent responses observed in patients with greater body surface area involvement or longer disease duration, as well as those who had no prior treatment with systemic therapies or discontinued systemic therapies, demonstrate the potential for this non-steroidal topical treatment to help provide disease control.”
Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon
“Atopic dermatitis is a chronic condition that can affect patients in different ways over the course of their lives, and treatment needs can evolve with the disease.”
Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon
“For patients and their physicians, having a non-steroidal atopic dermatitis treatment option is critical.”
Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon
“These new pooled data reinforce the potential for VTAMA cream to help provide disease control across diverse patient types.”
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
* VTAMA demonstrated consistent response rates for disease severity and itch, measured by ≥75% improvement in Eczema Area and Severity Index (EASI75) and Peak Pruritus-Numeric Rating Scale (PP-NRS), across subgroups based on baseline percent body surface area (BSA) affected, disease duration, and prior use of systemic therapies among patients with moderate to severe atopic dermatitis(1,2)
Get started
Create a free account to read the full story.